The U.S. Food and Drug Administration (FDA) has named Compass’s psychedelic therapy a “breakthrough” in depression treatment, reported Bloomberg on January 7.

At this moment, a mental-health-care company in London, Compass Pathways Ltd, runs a clinical trial of their product containing hallucinogen psilocybin also found in psychedelic mushrooms on 216 patients.

The board is determined to deliver the best clinical trials in a scientific way, given the reputation of the psychedelic component. While scientists do not yet understand the mechanics and advocate the need for more research, political stigma around the topic has been stopping many companies.

Compass’s clinical test is expected to end this summer, while follow up procedures could take a couple of years. If the current clinical trial Phase 2B is successful, and psilocybin proves effective against treatment-resistant depression, even if scientists can not explain at this moment how it works, it would receive an approval.

The project co-founders, George Goldsmith and Ekaterina Malievskaia, reported that use of psychedelics and ketamine had helped founder’s son in 2014, when traditional treatment options against depression had proven ineffective. From that founders have derived the motivation to proceed with this controversial medical treatment.

Earlier Compass has also raised $58 million in funding from various investors, including Peter Thiel, Christian Angermayer, and Michael Novogratz.


Follow us on Facebook, Twitter, Telegram, or Youtube!